# Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

> **NCT03023631** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 48 (actual)

## Conditions studied

- Allogeneic Hematopoietic Stem Cell Transplant Recipient
- Hematopoietic and Lymphoid Cell Neoplasm

## Interventions

- **BIOLOGICAL:** Recombinant Human Papillomavirus Nonavalent Vaccine

## Key facts

- **NCT ID:** NCT03023631
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-04-23
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03023631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03023631, "Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03023631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*